All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM | DEC 2025 | DEC 2024 ~1.6:1 split | DEC 2023 ~31.3:1 split | DEC 2022 | DEC 2021 ~1.6:1 split |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $116 | $117 | $106 | $113 | $102 | $7 |
| Cost of Revenue | $7 | $5 | $4 | $5 | $5 | – |
| Gross Profit | $113 | $111 | $102 | $109 | $97 | – |
| Operating Expenses | ||||||
| Selling & Marketing | $67 | $65 | $58 | $61 | $54 | – |
| General & Administrative | $24 | $21 | $16 | $15 | $17 | $19 |
| Research & Development | – | $14 | $12 | $14 | $17 | $69 |
| Provision for Doubtful Accounts | – | – | – | – | $0 | – |
| Total Operating Expenses | $129 | $105 | $90 | $176 | $88 | $95 |
| Operating Income | -$12 | $11 | $16 | -$67 | $9 | -$88 |
| Other Non-Operating Income (Expense) | -$2 | -$2 | -$2 | -$2 | – | -$0 |
| EBT (Earnings Before Tax) | -$12 | $14 | $23 | -$77 | $9 | -$88 |
| Income Tax Expense | $3 | $5 | $5 | $9 | $5 | – |
| Earnings from Continuing Ops | -$16 | $10 | $18 | -$85 | $4 | – |
| Minority Interest | $2 | $5 | $6 | $7 | $2 | – |
| Net Income | ||||||
| Net Income | -$20 | $10 | $18 | -$85 | $4 | -$88 |
| Per Share Data | ||||||
| Revenue Per Share | $1.16 | $1.13 | $1.03 | $1.72 | $48.64 | $3.59 |
| EPS (Basic) | -$0.17 | $0.06 | $0.14 | -$1.41 | $0.04 | -$43.05 |
| EPS (Diluted) | -$0.17 | $0.02 | $0.05 | -$1.41 | $0.03 | -$43.05 |
| Weighted Avg Shares (Basic) | 100.6M | 89.3M | 85.1M | 65.8M | 31.5M | 30.6M |
| Weighted Avg Shares (Diluted) | 100.6M | 103.2M | 102.3M | 65.8M | 31.5M | 30.6M |
| Shares Outstanding | 100.6M | 103.2M | 102.3M | 65.8M | 2.1M | 2.0M |
| Dividends Per Share | – | – | – | – | $21.45 | – |
Gyre Therapeutics (GYRE) financials: revenue, profit and margins
Gyre Therapeutics (GYRE) generated about $116 million in revenue and -$20 million in net income (a -16.8% net margin) over the trailing twelve months, growing at roughly 41.0% a year. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
What is Gyre Therapeutics's (GYRE) revenue?+
Gyre Therapeutics generated about $116 million in revenue over the trailing twelve months. Revenue has grown at roughly 41.0% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Gyre Therapeutics profitable?+
Gyre Therapeutics reported about -$20 million in net loss over the trailing twelve months, a net margin of roughly -16.8%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
What are Gyre Therapeutics's profit margins?+
Gyre Therapeutics runs a gross margin of about 96.7%, an operating margin of about -10.5%, a net margin of about -16.8%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
How fast is Gyre Therapeutics growing?+
Gyre Therapeutics's revenue has compounded at roughly 41.0% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside GYRE's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 1 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 28 Sept 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Pharmaceutical Preparations · Pick stocks to compare with GYRE
Held by ETFs
GYRE is in 3 US ETFs. The largest of them, with GYRE's weight in each:
Spot a number that looks wrong? Check it in GYRE's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing GYRE
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.